Cargando…

Response regarding Colombian regulation of biotherapeutic products

Detalles Bibliográficos
Autores principales:	Vaca, Claudia, Gaviria, Alejandro, Gómez, Carolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Organización Panamericana de la Salud 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645330/ https://www.ncbi.nlm.nih.gov/pubmed/29466518 http://dx.doi.org/10.26633/RPSP.2017.129

Ejemplares similares

Respuesta sobre la regulación colombiana de los productos bioterapéuticos
por: Vaca González, Claudia, et al.
Publicado: (2017)

Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case
por: Prada, Sergio I., et al.
Publicado: (2018)

Editorial: Characterization of biotherapeutic products
por: Rathore, Anurag S., et al.
Publicado: (2022)

West Nile Virus Antibodies in Colombian Horses
por: Mattar, Salim, et al.
Publicado: (2005)

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
por: Martin, Kyle P., et al.
Publicado: (2023)

Cyanobacterial Production of Biopharmaceutical and Biotherapeutic Proteins
por: Betterle, Nico, et al.
Publicado: (2020)

Editorial: Synthetic Live Biotherapeutic Products for Diseases
por: Chen, Ye, et al.
Publicado: (2022)

Response to letter regarding “Gastrointestinal foreign bodies in pet pigs: 17 cases”
por: Nakamae, Yoko, et al.
Publicado: (2022)

Double-positive T Lymphocytes Do Not Vary in Different Age Groups in Colombian Blood Donors
por: Gonzalez-Mancera, Miguel S., et al.
Publicado: (2020)

Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)

Integrated BioTherapeutics
por: Aman, M. Javad
Publicado: (2018)

Factors that influence clinical efficacy of live biotherapeutic products
por: Pot, Bruno, et al.
Publicado: (2021)

Metabolic Profiling of CHO Cells during the Production of Biotherapeutics
por: Coulet, Mathilde, et al.
Publicado: (2022)

IgY Antibodies as Biotherapeutics in Biomedicine
por: León-Núñez, Diana, et al.
Publicado: (2022)

Response to letter regarding “ACVIM consensus statement on pancreatitis in cats”
por: Forman, Marnin A., et al.
Publicado: (2021)

Response to letter regarding “ACVIM consensus statement on pancreatitis in cats”
por: Forman, Marnin A., et al.
Publicado: (2021)

Adverse drug reactions in hospitalized Colombian children
por: de las Salas, Roxana, et al.
Publicado: (2016)

In Regard to Barker
por: Goff, Peter H., et al.
Publicado: (2021)

Colombian Stakeholder Perceptions and Recommendations Regarding Fall Detection Systems for Older Adults
por: Avella-Rodríguez, Edna, et al.
Publicado: (2023)

Live Biotherapeutic Products, A Road Map for Safety Assessment
por: Rouanet, Alice, et al.
Publicado: (2020)

Live biotherapeutic products: the importance of a defined regulatory framework
por: Cordaillat-Simmons, Magali, et al.
Publicado: (2020)

From science to business: translating live biotherapeutic products to the clinic
por: Lluch-Senar, Maria
Publicado: (2023)

Response to Letter Regarding Article, "Biventricular Takotsubo Cardiomyopathy Associated with Epilepsy"
por: Hong, Ji Yeon
Publicado: (2016)

Response to Letter Regarding Article, "Stress-Induced Cardiomyopathy Presenting as Shock"
por: Yoo, Tae Kyung
Publicado: (2016)

A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
por: Stella, Salvatore Massimo, et al.
Publicado: (2022)

Letter to the Editor regarding Meta-analysis of the efficacy of gabapentin: a response
por: Masoud, Ahmed Taher, et al.
Publicado: (2022)

Author rebuttal to response regarding “Letter to the Editor regarding ‘Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?’”
por: Horn, Evelyn, et al.
Publicado: (2020)

In vivo selection of novel biotherapeutics
por: Ruozi, Giulia, et al.
Publicado: (2015)

Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

The Emerging Biotherapeutic Agent: Akkermansia
por: Kalia, Vipin Chandra, et al.
Publicado: (2021)

Regarding data visualization
por: Birnbaum, David
Publicado: (2021)

Response-letter to the editor regarding nutrient density of beverages in relation to climate impact
por: Smedman, Annika, et al.
Publicado: (2010)

Response to letter to editor regarding Variability of symmetric dimethylarginine in apparently healthy dogs
por: Kopke, Matthew A., et al.
Publicado: (2018)

Response to letter to editor regarding Seizure‐precipitating factors in dogs with idiopathic epilepsy
por: Forsgård, Johanna, et al.
Publicado: (2019)

Response to letter to editor regarding ECEIM consensus statement on equine metabolic syndrome
por: Durham, Andy E., et al.
Publicado: (2019)

Response to letter regarding “Clinical features, diagnosis, and survival analysis of dogs with glioma”
por: José‐López, Roberto, et al.
Publicado: (2022)

Generalized anxiety disorder scale (GAD-7) has adequate psychometric properties in Colombian general practitioners during COVID-19 pandemic
por: Monterrosa-Blanco, Angélica, et al.
Publicado: (2021)

Letter to the Editor Regarding: "The Role of Social Media on the Research Productivity of Neurosurgeons During the COVID-19 Pandemic"
por: Neupane, Durga, et al.
Publicado: (2023)

Lipid-lowering drug prescriptions in a group of Colombian patients
por: Gaviria-Mendoza, Andrés, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l8tvrnge6kane0elsbqpjg2ao0